A Review of Functional Neuroimaging in People with down Syndrome with and without Dementia
| dc.contributor.author | Lau, Lilian Suh Lih | |
| dc.date.accessioned | 2022-01-18T11:34:53Z | |
| dc.date.available | 2022-01-18T11:34:53Z | |
| dc.date.issued | 2021-09 | |
| dc.identifier.citation | Funmi Deinde et al. (2021) ‘A Review of Functional Neuroimaging in People with Down Syndrome with and without Dementia’, Dementia and Geriatric Cognitive Disorders Extra, 11(3), pp. 324–332 | en_US |
| dc.identifier.uri | http://hdl.handle.net/20.500.12904/15077 | |
| dc.description.abstract | Background: Individuals with Down syndrome (DS) are at high risk of dementia which is difficult to diagnose in DS. Neuroimaging has been identified as a potential tool to aid diagnosis by detecting changes in brain function. We carried out a review comparing functional neuroimaging in DS individuals with and without dementia. Summary: A literature search was conducted using PubMed to identify relevant studies. In DS subjects with dementia, fluorodeoxyglucose-positron emission tomography (PET) studies showed glucose hypometabolism particularly in the parietal and/or temporal regions whilst magnetic resonance spectroscopy studies showed increased myoinositol and decreased N-acetylaspartate. Ligand-based PET studies revealed significant Pittsburgh compound B binding in DS subjects over the age of 40, particularly if they had dementia. Key Messages: Neuroimaging may aid the early detection of dementia in DS; however, further longitudinal studies are required. | |
| dc.description.uri | https://www.karger.com/Article/FullText/520880 | en_US |
| dc.publisher | Dementia and Geriatric Cognitive Disorders Extra | en_US |
| dc.subject | Dementia | en_US |
| dc.subject | Down syndrome | en_US |
| dc.subject | Functional neuroimaging | en_US |
| dc.title | A Review of Functional Neuroimaging in People with down Syndrome with and without Dementia | en_US |
| dc.type | Article | en_US |
| rioxxterms.funder | Default funder | en_US |
| rioxxterms.identifier.project | Default project | en_US |
| rioxxterms.version | NA | en_US |
| rioxxterms.versionofrecord | 10.1159/000520880 | en_US |
| rioxxterms.type | Journal Article/Review | en_US |
| refterms.dateFOA | 2022-01-18T11:34:53Z | |
| refterms.panel | Unspecified | en_US |
| html.description.abstract | Background: Individuals with Down syndrome (DS) are at high risk of dementia which is difficult to diagnose in DS. Neuroimaging has been identified as a potential tool to aid diagnosis by detecting changes in brain function. We carried out a review comparing functional neuroimaging in DS individuals with and without dementia. Summary: A literature search was conducted using PubMed to identify relevant studies. In DS subjects with dementia, fluorodeoxyglucose-positron emission tomography (PET) studies showed glucose hypometabolism particularly in the parietal and/or temporal regions whilst magnetic resonance spectroscopy studies showed increased myoinositol and decreased N-acetylaspartate. Ligand-based PET studies revealed significant Pittsburgh compound B binding in DS subjects over the age of 40, particularly if they had dementia. Key Messages: Neuroimaging may aid the early detection of dementia in DS; however, further longitudinal studies are required. | en_US |
| rioxxterms.funder.project | 94a427429a5bcfef7dd04c33360d80cd | en_US |
